-- Novo Nordisk's diabetes and obesity drug sales recorded a sharp rise in India sales in April after it reduced prices of Wegovy and Ozempic to counter growing competition from generic semaglutide therapies, Bloomberg News reported Friday, citing Pharmarack data.
Sales of Wegovy, Ozempic and partner-branded products climbed 40% monthly to 32,000 units in April, which was the first full month since the Danish pharmaceutical group lowered starter-dose prices by up to 48%, the report noted.
India's overall GLP-1 market expanded 56% month over month in April to 414,000 units, driven by low-cost generic semaglutide products, the report noted. Eli Lilly remained the country's top-selling GLP-1 drugmaker.
Novo Nordisk did not immediately respond to' request for comment.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)